“Regulatory Predictability” Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
Executive Summary
FDA's new leadership should focus on improving "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 4
You may also be interested in...
FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests
As agency issues take center stage at a pharmacoeconomics meeting, American Enterprise Institute fellow recommends reorganizing review divisions to accelerate approval of orphan drugs.
Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market
Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market